Gyre Therapeutics (GYRE) Loans and Notes Receivables (2022 - 2026)
Gyre Therapeutics (GYRE) reported Loans and Notes Receivables of $3.8 million for Q1 2026, up 78.53% year-over-year from $2.1 million in Q1 2025, and down 32.3% on a QoQ basis from $5.6 million in Q4 2025.
Gyre Therapeutics (GYRE) has 5 years of Loans and Notes Receivables data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Loans and Notes Receivables rose 78.53% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 78.53% YoY) and the FY2025 annual result came in at $5.6 million, up 28.93% from the prior year.
- Loans and Notes Receivables retreated to $3.8 million in Q1 2026 per GYRE's latest filing, from $5.6 million in the prior quarter.
- Across five years, Loans and Notes Receivables topped out at $5.6 million in Q4 2025 and bottomed at $91000.0 in Q3 2024.
- The 5-year median for Loans and Notes Receivables is $693000.0 (2025), against an average of $1.8 million.
- The widest annual swing landed in 2023, when Loans and Notes Receivables tumbled 74.44%; it then surged 1024.16% in 2024.
- Tracing GYRE's Loans and Notes Receivables over 5 years: stood at $1.5 million in 2022, then plunged by 74.44% to $389000.0 in 2023, then surged by 1024.16% to $4.4 million in 2024, then gained by 28.93% to $5.6 million in 2025, then plunged by 32.3% to $3.8 million in 2026.
- Per Business Quant, the three latest GYRE Loans and Notes Receivables figures stand at $3.8 million (Q1 2026), $5.6 million (Q4 2025), and $693000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Loans & Notes Receiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.82 Mn |
| Dec 31, 2025 | 5.64 Mn |
| Sep 30, 2025 | 693,000.00 |
| Jun 30, 2025 | 499,000.00 |
| Mar 31, 2025 | 2.14 Mn |
| Dec 31, 2024 | 4.37 Mn |
| Sep 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Mar 31, 2024 | 356,000.00 |
| Dec 31, 2023 | 389,000.00 |
| Dec 31, 2022 | 1.52 Mn |